Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms

Published:2022-12-07 Issue:1 Volume:4 Page:241-245
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Maze Dawn¹^ORCID,Arusi Iyad²,Gupta Vikas¹^ORCID,Atenafu Eshetu G.³^ORCID,Malinowski Ann Kinga⁴,Shehata Nadine²

Affiliation:

1. Elizabeth and Tony Comper MPN Program Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

2. Division of Hematology Mount Sinai Hospital Special Pregnancy Program University of Toronto Toronto Ontario Canada

3. Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

4. Department of Obstetrics and Gynaecology Division of Maternal‐Fetal Medicine Department of Obstetrics and Gynaecology, Lunenfeld‐Tanenbaum Research Institute Mount Sinai Hospital University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.622

Reference21 articles.

1. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

2. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

3. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

4. Mutations and prognosis in primary myelofibrosis

5. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aspirin;Reactions Weekly;2023-04-29